In a cohort of 4,260 health-conscious individuals, delayed-release calcium-alpha-ketoglutarate combined with vitamins was associated with 1.8 years lower epigenetic age, while standard AKG and CoQ10 showed minimal or non-significant benefits. The findings suggest specificity in formulation matters more than ingredient alone, and future controlled trials are needed to establish causation.
Key Points
- Delayed-release AKG formulation linked to 1.8-year epigenetic age reduction
- Standard AKG supplementation showed negligible and non-significant benefit
- CoQ10 longitudinal benefit diminished after multivariate statistical correction
Longevity Analysis
This research demonstrates that supplement efficacy depends critically on formulation and delivery mechanism, not ingredient presence alone. The 1.8-year difference in epigenetic markers—a measure of cellular aging velocity—suggests that how compounds reach tissues matters as much as what compounds are used. For practitioners and individuals optimizing long-term health outcomes, this shifts focus from supplement shopping lists to delivery science and timing. The study also reveals the limitations of observational data in health enthusiast populations: healthy user bias remains a substantial confounding factor, meaning those taking supplements may differ fundamentally in unmeasured behaviors, genetics, or baseline health status from non-users, making attribution of benefit problematic without randomized control.
Original published by Wiley Aging Cell, by Kamil Pabis, Weilan Wang, Kumar Selvarajoo, Yelena V. Budovskaya, Vincenzo Sorrentino, Jan Gruber, Brian K. Kennedy .